Daiichi Ranbaxy Buy Gives Japanese Pharma Other Indian Firms
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's acquisition of a majority share of India's Ranbaxy Laboratories also would give the Japanese drug maker a chance to get a controlling interest in another Indian pharma, Zenotech. Ranbaxy owns 48 percent of Zenotech, and Daiichi would have to make a separate offer for majority shares of that company. Ranbaxy interests in other Indian pharmas are included in the larger acquisition deal, including 14.9 percent interests each in Jupiter Bioscience, Kribs Biochemical and Orchid Pharma. (Click here for more
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.